Regenxbio Market Capitalization from 2010 to 2024
| RGNX Stock | USD 10.01 0.46 4.82% |
Check Regenxbio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regenxbio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.2 M, Interest Expense of 6.5 M or Selling General Administrative of 47.8 M, as well as many indicators such as Price To Sales Ratio of 8.26, Dividend Yield of 0.0 or PTB Ratio of 2.64. Regenxbio financial statements analysis is a perfect complement when working with Regenxbio Valuation or Volatility modules.
Regenxbio | Market Capitalization |
Latest Regenxbio's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Regenxbio over the last few years. It is Regenxbio's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regenxbio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 495.95 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Regenxbio Market Capitalization Regression Statistics
| Arithmetic Mean | 1,154,929,104 | |
| Geometric Mean | 1,138,767,809 | |
| Coefficient Of Variation | 17.81 | |
| Mean Deviation | 187,457,072 | |
| Median | 993,007,825 | |
| Standard Deviation | 205,728,628 | |
| Sample Variance | 42324.3T | |
| Range | 542.7M | |
| R-Value | 0.62 | |
| Mean Square Error | 28156.1T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | 28,442,358 | |
| Total Sum of Squares | 592539.8T |
Regenxbio Market Capitalization History
About Regenxbio Financial Statements
Regenxbio investors use historical fundamental indicators, such as Regenxbio's Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Regenxbio. Please read more on our technical analysis and fundamental analysis pages.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. Regenxbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 372 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.